HOXA9 has the hallmarks of a biological switch with implications in blood cancers

Laure Talarmain; Matthew A. Clarke; David Shorthouse; Lilia Cabrera-Cosme; David G. Kent; Jasmin Fisher; Benjamin A. Hall

doi:10.1038/s41467-022-33189-w

Nature Communications (Oct 2022)

HOXA9 has the hallmarks of a biological switch with implications in blood cancers

Laure Talarmain,
Matthew A. Clarke,
David Shorthouse,
Lilia Cabrera-Cosme,
David G. Kent,
Jasmin Fisher,
Benjamin A. Hall

Affiliations

Laure Talarmain: Peter MacCallum Cancer Centre
Matthew A. Clarke: UCL Cancer Institute, University College London, Paul O’Gorman Building
David Shorthouse: Department of Medical Physics and Biomedical Engineering, Malet Place Engineering Building, University College London
Lilia Cabrera-Cosme: York Biomedical Research Institute, Department of Biology, University of York
David G. Kent: York Biomedical Research Institute, Department of Biology, University of York
Jasmin Fisher: UCL Cancer Institute, University College London, Paul O’Gorman Building
Benjamin A. Hall: Department of Medical Physics and Biomedical Engineering, Malet Place Engineering Building, University College London

DOI: https://doi.org/10.1038/s41467-022-33189-w
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 10

Abstract

Read online

HOXA9 plays an important role in acute myeloid leukaemia (AML), but its relevance for other blood malignancies is unclear. Here, the authors show that HOXA9 has a binary switch function that can clinically stratify AML patients, and model how the interactions with JAK2, TET2 and NOTCH impact myeloproliferative neoplasms.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal